Welcome to Justin Stindt Consultants, the international consulting agency specializing in the unique healthcare landscape of Spain. Spain’s healthcare system, with its 19 autonomous regions and a single payer National Health Service (NHS), demands a nuanced approach to pricing and reimbursement. Our team of experts provides insights into both the retail and hospital markets, navigating the complexities of entities like the AEMPS, Revalmed, and regional Health Technology Assessment (HTA) bodies. From understanding the pivotal role of Pharmacy and Therapeutics Committees (PTCs) to leveraging alternative pathways for drug access, Justin Stindt Consultants stands as your dedicated partner for pharma, biotech and medtech. Engage with us to ensure a successful market entry and optimal positioning in Spain’s intricate pharmaceutical landscape.
Market Access Mastery: Healthcare, Pricing & Reimbursement Pathways in Spain's Decentralized System
A Guide to Pricing and Reimbursement in Spain’s NHS Framework
Spain operates under a unique healthcare system, with 19 autonomous regions and a single payer National Health Service (NHS). Understanding the intricacies of pricing and reimbursement in Spain is crucial for successful market access.
Multi-Level Reimbursement and Pricing Negotiations in Spain’s Pharmaceutical Retail Market
In the retail market, the reimbursement process in Spain undergoes multiple iterations, with decisions made at both national and regional levels. The Spanish Agency of Medicines and Medical Devices (AEMPS) evaluates medicines to determine reimbursement eligibility. Only reimbursed medicines then enter pricing negotiations with the competent Spanish authorities. Key stakeholders include Revalmed establishing Therapeutic Positioning Reports, the Spanish Ministry of Health (notably the DGCCSF: General Direction of Common Health Services and Pharmacy) and the Interministerial Medicinal Products Pricing Committee.
Navigating Drug Administration in Spain's Unique Hospital Budget System
In the hospital market, unlike other EU countries, Spain does not utilize a Diagnosis-Related Group (DRG) system but still operates hospital budgets. Pharmacy and therapeutics committees (PTCs) play a vital role in ensuring the rational, effective, and safe administration of drugs within hospitals. Although decisions made by PTCs may vary across regions, certain criteria are commonly considered.
Alternative pathways also enable access to drugs in special situations, such as drugs not authorized in Spain but marketed in other countries, drugs under investigation, and those used under conditions other than those authorized.
Regional Influence in Spanish Healthcare: The Impact of Autonomous HTA Bodies
Spain’s autonomous regions have significant autonomy in managing and administering health services. Regional Health Technology Assessment (RHTA) bodies hold substantial power, often shifting decision-making authority away from the Ministry of Health. The Catalan Health Technology Assessment (CHTA) body, in particular, is the oldest and potentially the most influential regional HTA body in Spain. It’s crucial not to overlook the clinical guidelines or standard of care recommendations provided by regional HTA bodies. Risk-sharing agreements are also prevalent in some regions, such as Catalonia.
Optimizing Market Access in Spain
To optimize entry to the Spanish market, early preparation of market access activities is essential, ideally before pivotal trial readout and European Medicines Agency (EMA) approval. This allows for tailored strategies that align with Spain’s unique pricing and reimbursement landscape.
Justin Stindt Consultants, as an expert consulting agency, offers guidance on pricing & reimbursement pathways in Spain
At Justin Stindt Consultants, our team of specialists possesses extensive expertise in navigating the complexities of pricing and reimbursement in Spain.
We are an international consulting agency that can provide comprehensive guidance on engaging with regulatory bodies, understanding reference pricing mechanisms, and developing targeted market access strategies for Pharma, Biotech and MedTech. With the support of our consultants, your firm can effectively navigate the Spanish market and maximize your opportunities for success. Many pharma, biotech and medtech companies looking for a supplier have picked Justin Stindt Consultants as their service provider of choice for Market Access in Spain. Contact our specialists today to learn how our consulting agency can assist you in achieving your goals in Spain.
If you want to determine the price potential of your product, and are looking for a vendor, we develop Pricing & Reimbursement strategies.
If you have any questions on Pricing & Reimbursement pathways – Spain and for support in identifying the optimal pathways for your asset, please contact one of our consultants.
Meet one of our Strategic advice on Pricing & Reimbursement Pathways Spain experts
Get in touch with our expert
CLIENT TESTIMONIALS
